Bryon D. Johnson, PhD

Professor, Pediatrics (Hematology/Oncology/BMT) and Microbiology & Immunology

Locations

Microbiology & Immunology

Contact Information

General Interests

Cancer immunology and immunotherapy

Education

PhD, Immunology, University of Health Sciences/The Chicago Medical School (now Rosalind Franklin University), 1989
BS, Microbiology, Iowa State University, 1983

Research Interests

I am interested in understanding the biology and immunology of cancer, and uncovering novel immune-based approaches to treat cancer. My current research focuses on combining the following approaches to improve the use of cancer immunotherapy for treating both solid tumors and hematologic cancers: (1) immune checkpoint protein blockade, (2) adoptive transfer of cancer-reactive T lymphocytes, and (3) the use of metabolic inhibitors to increase T cell immunity.

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response.

(Zurko J, Chaney K, Astle JM, Johnson BD, Hari P, Shah NN.) Haematologica. 2021 10 01;106(10):2788-2790 PMID: 33853295 PMCID: PMC8485669 SCOPUS ID: 2-s2.0-85116219490 04/16/2021
Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting.

(Miller MS, Allen PJ, Brown PH, Chan AT, Clapper ML, Dashwood RH, Demehri S, Disis ML, DuBois RN, Glynn RJ, Kensler TW, Khan SA, Johnson BD, Liby KT, Lipkin SM, Mallery SR, Meuillet EJ, Roden RBS, Schoen RE, Sharp ZD, Shirwan H, Siegfried JM, Rao CV, You M, Vilar E, Szabo E, Mohammed A.) J Cancer Prev. 2021 Mar 30;26(1):71-82 PMID: 33842408 PMCID: PMC8020174 04/13/2021
Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.

(Badar T, Johnson BD, Hamadani M.) Bone Marrow Transplant. 2021 03;56(3):683-685 PMID: 32782349 SCOPUS ID: 2-s2.0-85089247553 08/13/2020
Synchronous effects of targeted mitochondrial complex I inhibitors on tumor and immune cells abrogate melanoma progression

(AbuEid M, McAllister DM, McOlash L, Harwig MC, Cheng G, Drouillard D, Boyle KA, Hardy M, Zielonka J, Johnson BD, Hill RB, Kalyanaraman B, Dwinell MB.) iScience. 25 June 2021;24(6) SCOPUS ID: 2-s2.0-85107963806 06/25/2021
STING Activated Tumor-Intrinsic Type I Interferon Signaling Promotes CXCR3 Dependent Antitumor Immunity in Pancreatic Cancer.

(Vonderhaar EP, Barnekow NS, McAllister D, McOlash L, Eid MA, Riese MJ, Tarakanova VL, Johnson BD, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58 PMID: 33548597 PMCID: PMC8081932 SCOPUS ID: 2-s2.0-85104314508 02/07/2021
Irradiation of the kidneys causes pathologic remodeling in the nontargeted heart: A role for the immune system.

(Lenarczyk M, Laiakis EC, Mattson DL, Johnson BD, Kronenberg A, North PE, Komorowski R, Mäder M, Baker JE.) FASEB Bioadv. 2020 Dec;2(12):705-719 PMID: 33336158 PMCID: PMC7734425 12/19/2020
Utilization and Cost Implications of Hematopoietic Progenitor Cells Stored for a Future Salvage Autologous Transplantation or Stem Cell Boost in Myeloma Patients.

(Chhabra S, Thapa B, Szabo A, Konings S, D'Souza A, Dhakal B, Jerkins JH, Pasquini MC, Johnson BD, Hari PN, Hamadani M.) Biol Blood Marrow Transplant. 2020 11;26(11):2011-2017 PMID: 32717431 SCOPUS ID: 2-s2.0-85090300711 07/28/2020
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial.

(Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, Fenske TS, Dropulić B, Orentas R, Hari P.) Nat Med. 2020 10;26(10):1569-1575 PMID: 33020647 SCOPUS ID: 2-s2.0-85092105030 10/07/2020
Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia.

(Shah NN, Jerkins JH, Johnson BD, Hari P.) JCO Oncol Pract. 2020 09;16(9):613-614 PMID: 32603254 SCOPUS ID: 2-s2.0-85090870606 07/01/2020
Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

(Shah NN, Johnson BD, Fenske TS, Raj RV, Hari P.) Blood Adv. 2020 05 26;4(10):2119-2122 PMID: 32407473 PMCID: PMC7252557 SCOPUS ID: 2-s2.0-85086848668 05/15/2020
Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice.

(Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q.) Blood Adv. 2019 10 22;3(20):3099-3110 PMID: 31648333 PMCID: PMC6849959 SCOPUS ID: 2-s2.0-85074935557 10/28/2019
Potentiation of Kras peptide cancer vaccine by avasimibe, a cholesterol modulator

(Pan J, Zhang Q, Palen K, Wang L, Qiao L, Johnson B, Sei S, Shoemaker RH, Lubet RA, Wang Y, You M.) EBioMedicine. November 2019;49:72-81 SCOPUS ID: 2-s2.0-85074132937 11/01/2019

Bryon D. Johnson, PhD